Posts by: Catarina Silva

Catarina Silva

February 8, 2019February 8, 2019

GE Healthcare, Vanderbilt University Medical Center to Develop Apps that Predict Immunotherapy Responses

News

GE Healthcare and Vanderbilt University Medical Center (VUMC) have established a five-year partnership aimed at developing new diagnostic tools to predict how an immunotherapy will work — as far ... Read more

October 2, 2018

Boehringer Buys ViraTherapeutics’ Shares to Expand Oncolytic Virus Program

News

Boehringer Ingelheim has bought all ViraTherapeutics’ shares, acquiring the company’s oncolytic virus platform and treatment candidates. The deal totaled €210 million (almost $247 million), and was based on a stock option agreement ... Read more

September 26, 2018September 26, 2018

First Patient Dosed in Phase 1/2 Trial Assessing CBT-101 Combos in Liver, Kidney Cancers

News

CBT Pharmaceuticals has dosed the first participant in its Phase 1/2 clinical trial assessing the safety and tolerability of CBT-101, in combination with PD-1 inhibitors, in advanced or metastatic hepatocellular carcinoma (HCC) ... Read more

September 11, 2018September 11, 2018

StemVacs Cancer Vaccine Shows Safety in Phase 1 Study and May Be Eligible for Right to Try, Therapeutic Solutions Says

News

StemVacs, a cell-based immunotherapy vaccine platform that targets cancer stem cells, was well-tolerated by 10 patients with multiple advanced cancers who took part in a Phase 1 safety trial, ... Read more

September 4, 2018

Adlai Nortye Opens Boston Site to Advance Cancer Treatments

News

Adlai Nortye has opened its first U.S. innovation center, in Boston, Massachusetts. The China-based company is dedicated to the development of treatments for metabolic diseases and cancer. The Boston ... Read more

August 10, 2018August 10, 2018

Seattle Children’s Hospital Enrolling Patients with Advanced Solid Tumors for Study of CAR T-cell Immunotherapy

News

Seattle Children’s Hospital is enrolling children and young adults with specific and advanced solid tumors in a Phase 1 clinical trial assessing whether T-cell immunotherapy can treat these abnormal ... Read more

September 28, 2017

Adjuvant Opdivo Delays Recurrence in Advanced Melanoma Patients, CheckMate-238 Study Shows

News

Advanced melanoma patients at high risk of recurrence after surgery fare better if given Opdivo (nivolumab) compared to the standard of care Yervoy (ipilimumab), according to data presented at the European Society ... Read more

Pin It on Pinterest